We report a case of Candida albicans prosthetic valve endocarditis in a patient who was still alive 1 year following a homograft aortic root and valve replacement and antifungal therapy. Only 33 other cases of successfully treated fungal prosthetic valve endocarditis have been reported. We review these 33 cases and six cases of late recurrence following treatment, as well as the clinical features, diagnosis, and options for treatment of fungal prosthetic valve endocarditis.
The first case report of fungal prosthetic valve endocarditis was published in 1964 by Newman and Cordell [1] , who described a patient with aspergillus infection affecting a mitral valve prosthesis. Since that time, numerous cases of fungal prosthetic valve endocarditis have been reported. However, despite aggressive medical and surgical intervention, the associated mortality rate remains extremely high.
We report a case in which a patient with Candida albicans prosthetic valve endocarditis was still alive 1 year following homograft aortic root and valve replacement and antifungal therapy. In reviewing the literature published between 1964 and the present, we found only 33 other cases of fungal prosthetic valve endocarditis that were successfully treated. We defined an outcome as successful if the patient was still alive and had no evidence of active disease 1 year following the initial diagnosis of fungal prosthetic valve endocarditis, and we defined a late recurrence as any recurrence of the disease thereafter. This article presents these 34 successfully treated cases as well as six cases of late recurrence and reviews the literature regarding diagnosis and management of this disease.
Case Report
A 52-year-old man from India with non-insulin-dependent diabetes mellitus who initially underwent aortic valve replacement because of Streptococcus sanguis endocarditis presented 3 months later with C. albicans prosthetic valve endocarditis.
In May 1994 the patient presented with shortness of breath and was found to have severe aortic insufficiency, an aortic valve vegetation, and a pseudoaneurysm on the noncoronary cusp of the aortic valve. S. sanguis endocarditis was diagnosed, and he underwent aortic valve replacement. The postoperative course was complicated by a pericardial effusion, and a pericardial 1 week after aortic valve replacement was positive for C. albicans. Transesophageal echocardiography demonstrated an abnormal area around the prosthetic valve that was consistent with dissection and bleeding seen at the time of the initial surgery. Indium scanning demonstrated bilateral uptake in the lungs, but no tracer was taken up in the heart. The C. albicans isolated in the single blood culture was considered a possible contaminant, but the patient received fluconazole (200 mg orally once a day for 10 days) and became afebrile. Eight subsequent blood cultures were all negative. Two blood cultures done on an outpatient basis 1 month later (12 and 13 July) were also negative.
The patient was well until August, when he began having fevers. On 13 August the patient was admitted, and five sets of blood cultures were positive for C. albicans. Physical examination findings were notable for a temperature of 39.5°C and a grade 2/6 systolic ejection murmur over the precordium, which was unchanged and heard loudest at the left-upper-sternal border; there were no peripheral stigmata of endocarditis.
On admission the WBC count was 15.2 X 103/mm3 (79% polymorphonuclear leukocytes, 12% lymphocytes, and 7% monocytes). Chest radiographic findings were significant for evidence of cardiomegaly without infiltrates or effusions, and electrocardiography showed sinus tachycardia at 104 beats/min and a P-R interval of 0.24.
The patient started receiving amphotericin B (1 mg/kg intravenously) and 5-fluorocytosine (1.5 g orally four times a day). A CT scan of the chest demonstrated a large loculated pericardial effusion with a suggestion of hemorrhagic exudate within it (figure 1). On transesophageal echocardiography there was a large tissue density surrounding the aortic valve, with another density anterior to or possibly invading the right atrium as well as 2 + aortic insufficiency (figure 2).
The patient underwent surgery on 16 August. The intraoperative findings were consistent with those of the preoperative echocardiography. There was extensive destruction ofthe aortic root and annulus, with dehiscence of the prosthetic valve. Excision of the proximal ascending aorta, with debridement of the infected area, was carried out. A root replacement was then performed with use of a cryopreserved aortic valve homograft, and the coronary ostia were reimplanted. He underwent surgery again 3 days later (19 August) for additional mediastinal debridement, and mediastinal drains were placed. The wound was irrigated with amphotericin B (50 mg/L of 5% dextrose water).
By postoperative day 5 (21 August), pressors were no longer required and the patient was extubated. Anterior mediastinal cultures of specimens obtained during surgery (16 August) yielded C. albicans and Staphylococcus epidermidis. A small vegetation measuring 0.3 cm in greatest dimension was identified on one of the valve leaflets. Microscopic sections of the vegetation showed innumerable fungal hyphae and yeast forms consistent with C. albicans. Vancomycin and gentamicin were added to the treatment regimen, but gentamicin was withdrawn 36 hours later when mild renal insufficiency developed.
Rifampin (300 mg orally twice a day) was added to the regimen 15 days postoperatively for synergistic treatment of possible S. epidermidis prosthetic valve endocarditis. No evidence ofperipheral embolization appeared during the patient's hospitalization or has to date. The patient received a total of 2 g of amphotericin (30 mglkg) plus 5-fluorocytosine and 40 days of therapy with vancomycin and rifampin. He was discharged on 25 September and continued taking fluconazole (200 mg orally once a day) for chronic suppression. Chest CT and transesophageal echocardiography repeated at the time of discharge revealed significant improvement. The CT still demonstrated a right mediastinal collection, but it was smaller than on the initial CT, and transesophageal echocardiography showed the homograft in the aortic position with normal function.
The patient has continued receiving fluconazole (200 mg/d). He has done well and has had no complications related to valvular dysfunction or infection. Transesophageal echocardiography repeated on 24 May 1995 showed the homograft in the aortic position with normal function; a small echogenic collection surrounding the right atrium, which was unchanged NOTE. Data were obtained by a literature search and cross-referencing of the tenn prosthetic valve with endocarditis and fungus with endocarditis. Other case reports may exist that were not found with this searching method. Ampho = amphotericin; Antibx = antibiotic therapy; AVR = aortic valve replacement; DM = diabetes mellitus; 5-FC = 5-fluorocytosine (flucytosine); MVR = mitral valve replacement; NA = data not available; ND = not done; PR = present report; RHD = rheumatic heart disease; TVR = tricuspid valve replacement; + = positive; -= negative.
since the previous transesophageal echocardiography on 23 September 1994; and no valvular vegetations.
Literature Review of Successfully Treated Cases and Late Relapses
Since 1964, 33 cases of successfully treated fungal prosthetic valve endocarditis have been reported (table 1) . However, adequate data are available for only 27 of the cases. C. albicans was the causative agent in the majority of cases, followed by other Candida species. Aspergillus was the next most frequent pathogen. Fungal endocarditis in the remaining patients was caused by Cryptococcus neoformans (one patient) and Torulopsis glabrata (one patient). Infection involved a prosthetic valve in 21 cases and a homograft in 11. Fifteen of the patients were men and 12 were women, a circumstance consistent with cm 1996;22 (February) 2 [32] 3 [33] 4 [34] 5 [ prior reports showing fungal prosthetic valve endocarditis to be more common in men than in women [30] . The majority of patients presented with fever, although 11 patients presented with embolic phenomena as well. This is not surprising, given the high predilection of fungal endocarditis to embolize. Reports have indicated the incidence of embolization to be from 41 % to 70% [31] . Use ofantibiotics was the predisposing factor in most cases.
According to most sources, 50% of patients with fungal endocarditis have negative blood cultures [2, 4] . Although data regarding culture results were limited, in the cases we reviewed, only 57% of the patients had positive blood cultures. In two cases, however, diagnosis was made by biopsy of the emboli. Time from initial surgery to diagnosis of fungal prosthetic valve endocarditis ranged from 1 day to 3 years, but most of the patients presented 4 months to 1 year after initial surgery.
While all 34 cases of fungal prosthetic valve endocarditis listed in table 1 have been reported as treatment successes,  table 2 illustrates the fact that recurrences may occur months to years after apparently successful therapy. In 1985 Svirbelyet al. [35] reported a case ofHistoplasma capsulatum endocarditis affecting a mitral and aortic porcine bioprosthesis. The patient was treated with mitral valve replacement, aortic valve replacement, 1.78 g of amphotericin, and rifampin but died 18 months later of embolic phenomena. Rubinstein et al. [34] described a case ofrelapse 14 months after apparent recovery, and Samelson et al. [33] reported a case of recurrence after 7 years of suppressive therapy with 5-fluorocytosine. Galgiani and Stevens [32] also described late recurrence in two patients 12 and 29 months, respectively, after their fungal infection was believed to be cured. These cases are indicative of the fact that long-term follow-up is necessary and that although patients who are still alive 1 year following therapy may be considered treatment successes, perhaps they can never be deemed cured. Hence, while we report our case as a treatment success, chronic suppression will be maintained with fluconazole.
Discussion
Fungi are important causes of prosthetic valve endocarditis; they are responsible for 9.6% of early cases (of onset within 60 days after insertion of the prosthesis) and for 4.3% of late cases of onset >60 days after insertion of the prosthesis) [37] .
C. albicans is the most common fungal pathogen, accounting for 10%-15% of all cases of prosthetic valve endocarditis [4] . Other Candida species and Aspergillus species are the next most common pathogens. Other fungi known to cause prosthetic valve endocarditis include Histoplasma capsulatum [35] , C. neoformans [16] , Mucor species [38] , Trichosporon cutaneum [39] , and saprophytic fungi such as Curvularia geniculata [40] , Phialophora mutabilia [41] , Hormodendrum dermatitidis [42] , and members of the genera Saccharomyces [43] , Paecilomyces [44] , and Penicillium [45] .
Open-heart surgery is a predisposing factor for fungal endocarditis [46] . Although the portal of entry of infection is often difficult to determine, fungi have been isolated from the heartlung machine, contaminated intravenous solutions, infected suture, teflon patches, and contaminated prostheses [47] . Aspergillus is an airborne organism and therefore may implant itself directly on the exposed heart at the time of surgery or infect the respiratory tract during the postoperative period, when mechanical ventilation is depressing normal pulmonary defense mechanisms [3] . Candida and Torulopsis species are normal commensals of the gastrointestinal tract, and Candida is part of the normal flora of the skin and oropharynx. Their invasiveness is enhanced when the bacterial flora are suppressed by broad-spectrum antibiotics. Patients undergoing prolonged treatment with antibiotics may thus be predisposed to candida and torulopsis infection [48] .
Furthermore, patients undergoing cardiovascular surgery are commonly treated with prophylactic antibiotics. Therefore, fungal infection may occur following these procedures. In addition to cardiothoracic surgery and use of antibiotics, other factors that predispose to fungal prosthetic valve endocarditis include chronic debilitating disease, sepsis, use of steroids, diabetes mellitus, and immunosuppressive therapy.
The diagnosis of fungal prosthetic valve endocarditis is often difficult and challenging. Clinical signs and symptoms may be indistinguishable from those of bacterial endocarditis, and blood cultures are negative in 25%-50% of cases [2, 11] . Performance of blood cultures by the lysis-centrifugation method improves recovery of the organism. Serological tests, including the following, have been used adjunctively in the diagnosis of candida endocarditis: Candida antibody precipitin reactions, counterimmunoelectrophoresis, immunodiffusion, immunofluorescence, and agglutination tests. However, given the fact that there is a high rate of false-positive results with use of the antibody detection systems and that findings with the Candida antigen detection systems have been equivocal, these techniques are no longer recommended [49] .
Fungal vegetations are usually very large and invade adjacent myocardium; therefore, transthoracic and transesophageal echocardiography are useful diagnostic procedures. As stated earlier, embolization to major blood vessels is a common complication of fungal prosthetic valve endocarditis [50] . Biopsy or surgical excision of the embolus and identification of fungi may be helpful in establishing a diagnosis of fungal prosthetic valve endocarditis. In conclusion, when blood cultures are negative but symptoms and signs of endocarditis are noted following prosthetic valve placement, fungal prosthetic valve endocarditis should be suspected. Patients should be evaluated by means of multiple blood cultures (performed by the lysis centrifugation method), transesophageal echocardiography, and biopsy of emboli (if necessary).
The consensus in the current literature is to treat fungal prosthetic valve endocarditis with surgical replacement of the involved valves, followed by antifungal therapy [1, 23, 28, 31, 34, 47, 51] . Amphotericin B is the drug of choice for fungal endocarditis [49] . Patients should receive 1.5 -2 g of amphotericin [49] . Given the in vitro data demonstrating synergy between amphotericin Band 5-fluorocytosine, most investigators advocate the use of 5-fluorocytosine as well [2, 51, 52] . While some authors have suggested giving 500 mg of amphotericin prior to valve replacement, delay of valve replacement increases the risk of embolization. We therefore advocate early valve replacement followed by administration of 2 g of amphotericin B. It is noteworthy that there have been several reports of patients successfully treated with antifungal therapy alone [18, 22] . However, until additional studies to support these regimens are conducted, antifungal therapy alone cannot be recommended.
Even when fungal prosthetic valve endocarditis is recognized early and appropriate therapy is instituted, the results of therapy remain dismal, with a survival rate of <20% [3, 16, 34] . This is due in part to the fact that even when cardiac vegetations are removed, additional foci persist and reseed implanted prosthetic valves. In addition, the antifungal agents amphotericin and flucytosine penetrate poorly into tissues, fungal vegetations, and artificial blood clots, thus permitting fungi to survive [3] . It is not surprising that recurrences long after completion of apparently successful therapy have been reported. Johnston et al. [36] have suggested that in order to decrease the risk of recurrence, lifelong suppressive therapy with an azole compound (such as fluconazole, once a day) should be given indefinitely after a patient completes a course of treatment with amphotericin B. While there have been no controlled trials to evaluate this regimen, it seems prudent to maintain patients' conditions with lifelong antifungal suppression. Finally, longterm follow-up ofall patients with fungal prosthetic valve endocarditis is essential.
